Delivery Order SPE2DB25D3008-SPE2DB25FRDKD
- Not listed
- The Defense Logistics Agency awarded a $4,168.51 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Teriparatide 560mcg/2.24ml pens. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The award is non-set-aside and was competitively awarded. Performance will be completed by July 25,...
- The Defense Logistics Agency awarded a delivery order valued at $4,076.99 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560mcg/2.24ml pens on May 27, 2025, with an ultimate completion date of May 28, 2025. This firm fixed price, competitively awarded contract involves no set-aside designation and specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child delivery order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $5,286.27 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Teriparatide 560mcg/2.24ml pens on September 8, 2025, with completion scheduled for September 9, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle...
- The Defense Logistics Agency awarded a delivery order valued at $3,388.67 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560mcg/2.24ml pens on May 30, 2025, with completion scheduled for June 2, 2025. This firm fixed-price delivery order, issued without set-aside designation, represents a competitive award to the pharmaceutical distributor's Conshohocken, Pennsylvania corporate office. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Teriparatide 560mcg/2.24mL pens valued at $6,554.84 with a firm fixed price structure. The order was competitively awarded without a set-aside designation and is scheduled for completion by September 30, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this delivery from its corporate office location in the same city. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,422.77 to AmerisourceBergen Drug Corp for Teriparatide 560 MCG/2.24 ML pen injections on August 18, 2025, with a completion date of August 19, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under the company's larger Indefinite...
- The Defense Logistics Agency awarded a $6,226.08 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Teriparatide 560mcg/2.24ml pen injectors. The contract represents a non-set-aside, competitively awarded delivery order with an ultimate completion date of August 11, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC)...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency valued at $9,296.70 for Teriparatide 560mcg/2.24ml pens with an ultimate completion date of August 1, 2025. The contract, awarded July 31, 2025, employs firm fixed-price pricing and carries no set-aside designation, indicating competitive award. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $41,615.46 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560mcg/2.24mL pen injections. The contract, issued on September 9, 2025, with an ultimate completion date of September 10, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a $2,619.84 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Teriparatide 560mcg/2.24mL pen injections, with an ultimate completion date of August 1, 2025. This firm fixed-price contract, awarded without set-aside designation through competitive procurement, is a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be...
- SPE2DB25D3008Indefinite Delivery Contract
- SPE2DB25D3008-SPE2DB25FRDKDDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $32,094.99 to AmerisourceBergen Drug Corp for the supply of Teriparatide 560mcg/2.24ml pens on September 25, 2025, with completion scheduled for September 26, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's larger contract vehicle with DLA. This delivery order is a child action under AmerisourceBergen Drug Corp's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military and veteran healthcare systems. The company's contract awards with DLA demonstrate its capability to fulfill diverse pharmaceutical needs across multiple therapeutic domains through open competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $32.1k | 9/25/25 |